Scientists transform pee into material fit for medical implants
Scientists have developed a method that can transform human urine into the hard mineral in bones and tooth enamel.
The research, funded by the U.S. military's Defense Advanced Research Projects Agency (DARPA), uses yeast to break urine down into hydroxyapatite, a form of calcium used in bone and dental implants.
And hydroxyapatite isn't useful only for implants — the researchers behind the study said the material could be used in archaeological restoration, as biodegradable alternatives to plastic, and as building materials for construction projects. They published their findings May 6 in the journal Nature Communications.
"This process achieves two goals at the same time," study co-author David Kisailus, a professor of materials science and engineering at the University of California, Irvine, said in a statement. "On the one hand, it helps remove human urine from wastewater streams, mitigating environmental pollution and the buildup of unwanted nutrients; and on the other hand, it produces a material that can be commercially marketed for use in a variety of settings."
Hydroxyapatite is a tough solid containing charged molecules of calcium, phosphate and hydroxide. It's naturally occurring, as it is the primary component in both bones and teeth. This makes it useful in medical implants because it's not likely to be rejected by the body and can stimulate further growth.
However, synthesizing the mineral is expensive, and some methods of doing so produce toxic intermediate chemicals. In mammals such as humans, hydroxyapatite is secreted by specialized cells called osteoblasts that draw in calcium phosphate from body fluids. But these cells don't live very long or divide frequently, which makes harnessing them at industrial scales challenging.
Related: Are cavities 'contagious'? Tooth-decay yeast can pass from moms to babies
To find another way of producing hydroxyapatite, the researchers turned to Saccharomyces boulardii, a type of yeast. Found on the skins of tropical fruits like lychee, the yeast species is commonly used as a probiotic.
RELATED STORIES
—Astronauts could ditch diapers on spacewalks thanks to new device that let's them drink their pee
—A woman kept getting drunk despite not drinking. Fungi in her gut were brewing their own alcohol.
—New urinal designs could prevent up to 265,000 gallons of urine from spilling onto the floor each day
By applying some genetic tweaks to this yeast, the scientists transformed it into what they call an "osteoyeast" that breaks down urea to release hydroxyapatite. Urea is a waste product formed when the body breaks down proteins, and it's then filtered by the kidneys and excreted in urine. The process of transforming the urea produces a gram of hydroxyapatite for every liter of urine, the scientists reported.
"This process to yield hydroxyapatite, or bone mineral, takes less than one day," Kisailus said. "The fact that it uses yeast as a chassis, which is inexpensive and can be placed in large vats at relatively low temperatures — think about beer that's made via fermentation processes and is well scaled — shows that this can be done easily without major infrastructural needs, and that has the added benefit of making it accessible to developing economies."
With their method demonstrated, the scientists are now investigating ways to make it work at scale. They say that they hope to apply the process in order to 3D print hydroxyapatite-based materials for implants, plastics, construction and energy applications.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and scalability. Its model integrates telehealth consultations, electronic medical records, cloud-based pharmacy fulfillment and artificial intelligence (AI)-driven care routing — creating a seamless end-to-end user experience across conditions like mental health, dermatology, sexual wellness and weight management. HIMS' subscription-based approach reached 2.4 million subscribers in first-quarter 2025, with over 1.4 million using personalized solutions, reflecting strong demand for tech-enabled care. Central to Hims & Hers' strategy is its expanding investment in AI. The recent appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal move toward scaling intelligent, individualized care. Elshenawy brings over two decades of experience in AI, robotics and cloud infrastructure, and is tasked with enhancing diagnostics, automation and platform personalization. These efforts are supported by an $870 million upsized convertible notes offering, with proceeds earmarked for AI innovation and global expansion. Hims & Hers is also vertically integrating its operations through acquisitions in pharmacy and diagnostics, enabling greater control over fulfillment and care quality. Tools like MedMatch use data to route patients to the right care pathways, while new AI applications aim to automate and refine diagnosis and treatment recommendations. By blending direct-to-consumer infrastructure with advanced technology, Hims & Hers is enhancing healthcare delivery for millions — offering a scalable model that delivers high-quality, personalized care with efficiency. LFMD & DOCS' Digital-First Transformation LifeMD, Inc. LFMD has rapidly evolved into a comprehensive digital-first healthcare platform offering vertically integrated telehealth solutions. With LifeMD's nationwide physician network, proprietary electronic medical records and in-house pharmacy operations, it delivers personalized care at scale. LFMD supports recurring subscription models across multiple specialties, including weight management and primary care. LifeMD's tech-enabled ecosystem enhances clinical access, operational efficiency and long-term subscriber value through continuous innovation. Doximity, Inc. DOCS continues to redefine physician engagement through its digital-first strategy, offering HIPAA-compliant telehealth tools and AI-powered workflow enhancements. Doximity enables doctors to connect, consult and collaborate seamlessly within its professional network. DOCS' platform integrates secure messaging, eFax and personalized newsfeeds, reflecting Doximity's mission to streamline clinical operations and empower providers with intelligent, scalable solutions. HIMS' Price Performance, Valuation and Estimates Shares of Hims & Hers have gained 171% year to date, outperforming the industry's growth of 10.7%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 5.6X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 177.8% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report LifeMD, Inc. (LFMD) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
43 minutes ago
- Yahoo
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress
Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the stocks under $10 to buy now. On July 17, Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study of tegoprubart will be presented at the World Transplant Congress/WTC. The WTC will take place in San Francisco from August 2-6 this year. The oral presentation, titled 'Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,' will feature updated results from ~30 kidney transplant recipients. In addition to the oral presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?' A scientist in a laboratory holding a vial of medication developed by the biotechnology company. Furthermore, new preclinical data on tegoprubart's use for preventing rejection in non-human primates undergoing liver transplantation will be presented in a poster session. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand/CD40L pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis/ALS. While we acknowledge the potential of ELDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Michigan moms could soon have easier access to group prenatal care that's changing lives
Picture this: instead of rushing through a prenatal appointment alone, you join a circle of eight or so expectant parents due around the same time. Over 90 relaxed minutes, you learn about stress management and breastfeeding, get individual check-ins from your provider, and build real relationships with other parents-to-be who actually get what you're going through. This is the heart of CenteringPregnancy, and if new legislation moves forward, moms across Michigan could soon have better access to this kind of support. On July 1, the Michigan Senate passed Senate Bills 414 and 415, which would require both private insurers and Medicaid to cover these group-based prenatal care programs. Related: New CDC data shows that more pregnant women are unable to access prenatal care Why it matters: the science of community prenatal care The idea is simple: you get your prenatal care in a group setting, alongside other pregnant people. But the impact goes way beyond the check-up. CenteringPregnancy helps normalize the experience of motherhood, offering emotional support and measurable health benefits. Studies have shown major benefits: A 33–47% drop in preterm births in randomized trials, with even stronger effects for Black mothers—a meaningful step toward addressing racial disparities in birth outcomes. A 40% reduction in postpartum depression symptoms at six months, according to a meta-analysis. For families already facing barriers to care, these improvements are life-changing. More than medical care: building a village Beyond the metrics, the emotional benefit of group prenatal care is hard to overstate. CenteringPregnancy creates space for parents to share fears, questions, and excitement with people on the same journey. It turns what can feel like a medical transaction into a shared rite of passage. For many moms, it means leaving appointments feeling empowered, informed, and less alone. It can also help detect mental health challenges earlier, improve breastfeeding success, and reduce feelings of isolation that so often accompany pregnancy and postpartum life. What the Michigan bills would change The two bills passed by the Senate aim to make this model a standard part of care—not just a nice-to-have pilot. Senate Bill 414 would require private insurers who already cover prenatal care to include group prenatal care in their plans. Senate Bill 415 would permanently secure Medicaid coverage for CenteringPregnancy in Michigan. (Medicaid already reimburses for it—but this law would ensure it stays that way.) By putting these requirements into law, the state would ensure consistent, widespread access, even if budgets or administrations change. Related: New York is officially the first state to mandate PTO for prenatal care A model the rest of the country should be watching Supporters of the legislation see Michigan as a potential national example. They argue that expanding CenteringPregnancy access is one of the simplest ways to improve maternal and infant health while also saving money on avoidable NICU stays and complications. For families, it represents a shift away from fragmented, rushed care toward a model that's relational, supportive, and proven to work. As a mom of five kids who was underwhelmed with the traditional prenatal care model, I'm excited about a healthcare system that doesn't just provide clinical insights, but also human connection. What's more intimate, life-transforming, and support-group worthy than bringing a new baby into the world? Sources: CenteringPregnancy: A model of group prenatal care. 2023. Centering Healthcare Institute. CenteringPregnancy: A model of group prenatal care. Group prenatal care reduces risk of preterm birth. October 2016. YaleNews. Group prenatal care reduces risk of preterm birth. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. November 2019. Obstetrics & Gynecology. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. SB 414 and SB 415. July 2024. Michigan Legislature. SB 414 and SB 415.